Nurix Therapeutics, Inc.
For the period ended Feb 28, 2026. Filed Apr 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Feb 28, 2026 · Filed Apr 8, 2026
NRIX$15.88-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulated deficit · Totalstockholders’equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of November 30, 2024 | 75,870,718 | $76 | $1,265,536 | $150 | $(738,769) | $526,993 |
| Exercise of stock options | 37,428 | — | 221 | — | — | 221 |
| Vesting of restricted stock units | 242,923 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 83,730 | — | 1,252 | — | — | 1,252 |
| Stock-based compensation | — | — | 8,726 | — | — | 8,726 |
| Unrealized gain on available-for-sale marketable securities | — | — | — | 76 | — | 76 |
| Net loss | — | — | — | — | (56,351) | (56,351) |
| Balance as of February 28, 2025 | 76,234,799 | $76 | $1,275,735 | $226 | $(795,120) | $480,917 |
| Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulateddeficit · Totalstockholders’equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of November 30, 2025 | 101,807,484 | $102 | $1,541,766 | $105 | $(1,003,226) | $538,747 |
| Issuance of common stock in “at the market” financing, net of issuance costs | 1,000,000 | 1 | 17,993 | — | — | 17,994 |
| Exercise of stock options | 77,942 | — | 375 | — | — | 375 |
| Vesting of restricted stock units | 330,395 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 183,992 | — | 1,596 | — | — | 1,596 |
| Stock-based compensation | — | — | 9,404 | — | — | 9,404 |
| Unrealized loss on available-for-sale marketable securities | — | — | — | (49) | — | (49) |
| Net loss | — | — | — | — | (87,174) | (87,174) |
| Balance as of February 28, 2026 | 103,399,813 | $103 | $1,571,134 | $56 | $(1,090,400) | $480,893 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.